STOCKS TELEGRAPH

Tag: SGHT Stock Price

  • Sight Sciences (SGHT) Shares Soar Amidst Industry Event Buzz

    Sight Sciences (SGHT) Shares Soar Amidst Industry Event Buzz

    Sight Sciences, Inc. (NASDAQ: SGHT) observed a notable surge in its stock value during the after-hour session on Tuesday, marking an increase of 18.20% to $6.43. This rise followed a preceding uptick of 2.45% during the regular trading session, culminating in a closing price of $5.44. The upward momentum of SGHT stock on the US stock charts coincided with the revelation of trial outcomes, which are planned to be disseminated through both oral and poster presentations at a significant industry event.

    Sight Sciences (SGHT) disclosed findings from studies into two of its proprietary technologies. SGHT’s TearCare System and the OMNI Surgical System are intended to treat glaucoma and dry eye disease (“DED”). Two oral presentations and two poster displays at the next ASCRS Annual Meeting, which takes place in Boston, Massachusetts from April 5–8, are planned to highlight these discoveries.

    The OMNI technology is intended to improve the ability of surgeons to perform a thorough, minimally invasive, implant-free surgical surgery for individuals with primary open-angle glaucoma (“POAG”). Conversely, the TearCare technology facilitates a proprietary interventional procedure targeting diseased meibomian glands, offering localized heat therapy for adult patients grappling with evaporative DED stemming from meibomian gland dysfunction, when combined with manual expression of the meibomian glands.

    At ASCRS, SGHT intends to present supplementary data reinforcing the efficacy and safety profiles of its OMNI and TearCare technologies. In addition to the existing robust corpus of clinical evidence, the company will present fresh data showcasing compelling OMNI outcomes over a 36-month period, underscoring the enduring efficacy of OMNI. Furthermore, new TearCare data will be unveiled, endorsing the utilization of TearCare technology as a primary therapeutic modality for DED.

    These findings reaffirm the notion that TearCare stands as a preferred treatment option for DED linked to meibomian gland dysfunction. Phase 1 of the SAHARA trial demonstrated that the interventional TearCare procedure delivered statistically superior and sustained improvements in tear break-up time and various measures of meibomian gland secretion compared to treatment with Restasis. In phase 2 of the study, a single TearCare procedure surpassed the outcomes achieved with six months of Restasis in terms of alleviating signs and symptoms for patients.

  • Strategic Advancements Propel Sight Sciences (SGHT) Stock’s After-Hours Surge

    Strategic Advancements Propel Sight Sciences (SGHT) Stock’s After-Hours Surge

    During the after-market session on Tuesday, Sight Sciences, Inc. (NASDAQ: SGHT) witnessed a substantial surge in its stock value, indicating a sustained momentum in its market performance. SGHT shares experienced a notable increase of 8.67% after hours on the US stock market, reaching a price point of $4.51.

    Throughout the regular trading hours, SGHT displayed stability, with a modest yet significant rise of 0.73%, concluding the session at $4.15. This upward trajectory in SGHT’s stock price is largely attributed to a strategic advancement within the company’s operations.

    The Ergo-Series of the OMNI Surgical System, which Sight Sciences just introduced to the European market, caused quite a stir. This cutting-edge device is intended to let individuals with open-angle glaucoma undergo minimally invasive, implant-free glaucoma operations.

    Since its March 2023 premiere in the US, the Ergo-Series has become a popular choice among OMNI surgeons due to its improved ergonomics and specially designed cannula tip that allows for comfortable and accurate access to Schlemm’s canal.

    Building upon the positive reception from US surgeons, Sight Sciences has successfully obtained the CE Mark under the new EU Medical Device Regulation, thereby paving the way for the marketing of this upgraded version of its OMNI technology across Europe.

    The company is poised to showcase the improved handle ergonomics, simplified viscoelastic preparation, and new cannula tip design at the prestigious European Society of Cataract and Refractive Surgeons (“ESCRS”) Winter meeting in Frankfurt later this month.

    The remarkable ergonomic enhancements of the OMNI Ergo-Series hold promise for enhancing user-friendliness, potentially motivating surgeons to intervene earlier in appropriate cases. This proactive approach can play a crucial role in delaying disease progression and preserving vision, while also potentially reducing the medication burden for glaucoma patients.

    The redesigned Ergo-Series not only makes the device more intuitive to handle and operate but also ensures gentle and precise access to Schlemm’s canal, accompanied by improved tactile feedback, which instills confidence in surgeons throughout the procedure.

    These advancements further expand the accessibility of OMNI for surgeons treating various stages of open-angle glaucoma, marking a significant stride in the field of ophthalmic surgery.